Advanced search
Publication Cover
Expert Review of Vaccines Volume 21, 2022 - Issue 1
Submit an article Journal homepage
4,875
Views
3
CrossRef citations to date
0
Altmetric
Editorial

What are the challenges faced by COVID-19 vaccines?

Mohnad Abdallaa Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, PR ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1682-5547View further author information
ORCID Icon,
Amr Ahmed El-Arabeyb Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, EgyptORCID Iconhttps://orcid.org/0000-0003-0420-7191View further author information
ORCID Icon &
Xinyi Jianga Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, PR ChinaORCID Iconhttps://orcid.org/0000-0003-0074-6876View further author information
ORCID Icon
Pages 5-7 | Received 30 May 2021, Accepted 16 Nov 2021, Published online: 26 Nov 2021

References

  • Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–484.
  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
  • Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82.
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
  • King C, Sprent J. Dual nature of type I interferons in SARS-CoV-2-induced inflammation. Trends Immunol. 2021;42(4):312–322.
  • Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–726.
  • Abdalla M, El-Arabey AA, and Jiang X. Are the new SARS-CoV-2 variants resistant against the vaccine? Hum Vaccin Immunother. 2021;17:3489–3490.
  • Abdalla M, El-Arabey AA, and Jiang X. Progress in research on the S protein as the target of COVID-19 vaccines. Expert Rev Vaccines. 2021;20:769–772.
  • Trougakos IP, Terpos E, Zirou C, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021;19(1):208.
  • Bergamaschi C, Terpos E, Rosati M, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6):109504.
  • Terpos E, Trougakos IP, Apostolakou F, et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccin ation with the BNT162b2 mRNA vaccine. Am J Hematol. 2021;96(7):E257–e259.
  • Terpos E, Trougakos IP, Karalis V, et al. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021;96(9):E321–e324.
  • Terpos E, Gavria topoulou M, Ntanasis-Stathopoulos I, et al. The neutra lizing antibody response post COVID-19 vacc ination in patients with myeloma is highly dependent on the type of anti-myeloma tre atment. Blood Cancer J. 2021;11(8):138.
  • Paik DH, Farber DL. Anti-viral protective capacity of tissue resident memory T cells. Curr Opin Virol. 2021;46(20–26):20–26.
  • Mehta A, Michler T, Merkel OM. siRNA thera peutics against respir atory viral infecti ons-what have we learned for pot ential COVID-19 the rapies? Adv Healthc Mater. 2021;10(7):e2001650.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.